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Summary We have established ten transplantable human soft-tissue sarcoma (STS) xenografts grown as subcutaneous tumours in the
nude mouse. Nine xenografts originated from patients that needed chemotherapy in the course of their disease. The xenografts were tested
for their sensitivity to maximum tolerated doses of five anti-cancer agents. Growth of treated tumours was expressed as a percentage of
control tumour growth and a growth inhibition > 75% was measured for doxorubicin in 20% of the STS xenografts, forcycophosphamide in
30%/o, for ifosfamide in 200/o, for vincristine in 20%, whereas etoposide was not effective in the STS xenografts. In three out of ten STS
xenografts MDR1 mRNA was detectable, but this was not related to the resistance against doxorubicin, vincristine or etoposide.
Topoisomerase Ila mRNA expression levels did not reflect sensitivity to doxorubicin or etoposide. In all STS tissues, however, these levels
were lower than topoisomerase Ila mRNA in a drug-sensitive human ovarian cancer xenograft. Glutathione concentrations and the actvities
of glutathione S-transferase, glutathione peroxidase and glutathione reductase were not related to resistance against the alkylating agents or
doxorubicin. Of interest, in all STS tissues, glutathione S-transferase ic was the predominant isoenzyme present. In conclusion,
chemosenstivity of the STS xenografts reflects clinical response rates in phase 11 trials on the same compounds in adult STS patients.
Relatively low levels of topoisomerase Ila mRNA may partly account for intrinsic resistance against, for example, doxorubicin. Additional
factors must contribute to moderate responsiveness to alkylating agents.
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Adult soft-tissue sarcomas (STS) are malignant tumours ansing
in the extraskeletal connective tissues of the body. These rare
tumours are grouped together because of similarities in patholog-
ical appearance. clinical presentation and behaviour. Most impor-
tant prognostic factors are the histological grade. the site and the
size of the primary lesion. The comerstone of treatment is radical
surgery. Radiotherapy. preoperatively. intraoperatively or post-
operatively. may be applied to prevent local failure. especially in
cases of poor operability. narrow surgical margins. larger tumour
size or higher histological grade. Unfortunately. 40-60% of STS
patients will develop a recurrence or metastatic disease after
locoregional treatment for their primary lesion (Yang et al. 1993).
At the present time, advanced STS shows a poor response to the
currently used chenmothrapy regimens (Demetri and Elias. 1995).
Only a few drugs have activity in STS. ofwhich doxorubicin is best
known. The overall response rae of doxorubicin given as a single
agent is approximately 26% (Demetri and Elias. 1995). Various
doxorubicin-containing regimens have been studied, including a
complex combination ofcyclophosphamide. vincristine. doxorubicin
and dacarbazine (CYVADIC) resulting in a response rate of 28.4%
(Santoro et al. 1995). In the past decade. ifosfamide was also found
to be active in STS and supenror to its analogue cyclophosphamide
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(Bramwell et al, 1987: Dirix and Van Oosterom. 1989). The combi-
nation of doxorubicin and ifosfamide resulted in a response rate of
28.1%. which was. however. not superior to CYVADIC or to single-
agent doxorubicin (Santoro et al. 1995).
Not much is known about the reasons for the moderate respon-
siveness of STS in the clinic. Stein et al (1996) reviewed 18
studies on the expression ofpI70-glycoprotein (Pgp) or the MDRI
gene in bone sarcomas and STS. The intrinsic expression of the
MDRJ gene in untreated tumours appeared to be extremely vari-
able. with an average of 43% of positive cases. In contrast to
childhood STS. a significant correlation with the response to
chemotherapy was not found in adult STS. Far less is known about
the possible implication of other drug resistance mechanisms in
STS. Such mechanisms may include alteration of DNA topoiso-
merase H. which is the nuclear target for doxorubicin and etopo-
side (Nitiis and Beck. 1996) or glutathione and glutathione-
dependent enzymes involved in the detoxification of alkylating
agents such as cyclophosphamide and ifosfamide (Black and Wolf.
1991; Tew. 1994: Hayes and Pulford. 1995).
In the last few years. we have established several human tumour
xenografts derived from adult STS for subcutaneous (s.c.) growth
in the nude mouse. These xenografts were analysed for their
response to anti-cancer agents commonly in use in the clinic. In an
attempt to identify the mechanisms underlying the moderate
chemosensitivity ofSTS. we assessed the expression ofthe MDRJ
gene. topoisomerase Ila expression. the glutathione content and
the activities of glutathione-dependent enzymes. The outcome of
these parameters was compared with the in vivo response to the
individual anti-cancer agents.
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Table 1 Human soft-tbssue sarcoma xenografts grown s.c. in nude mice
Xanograft Histology Tda Range
S.Ba Liposarcoma 10.0 (7.0-14.0)
WLS-160 Liposarcoma 7.0 (5.5-9.0)
S.Lt Synovial sarcoma 11.0 (6.5-17.5)
S.To Synovial sarcoma 14.5 (12.0-18.0)
S.Hh Leiomysarcoma 19.5 (18.0-21.0)
S.Hu Leomyosarcoma 14.5 (11.5-17.5)
S.La(C) Malignat fbrous histiocytoma 12.5 (10.0-13.0)
S.Zu Maignant fibrous histiocytoma 5.0 (3.0-6.5)
S.Ho Neurofibrosarcoma 5.0 (4.0-6.5)
S.Sin Neurofbrosarcoma 6.0 (5.5-6.5)
aT, tumourvolume doubling time in days. bEstabWished from a cell line.
MATERIALS AND METHODS
Animals and transplantation
Female athymic nude mice (NMRI/Cpb orHsd:Athymic Nude-nu)
were purchased from Harlan CPB (Zeist, The Netherlands) at the
age of 6 weeks. Animals were maintained in isolation in cages
with paper filter covers under controlled atmospheric conditions.
Cages. covers. bedding. food and water were sterilized and
changed weekly. Animal handling was done in a laminar down-
flow hood. Ethical approval was obtained from the 'Dutch
Committee for Experimental Animals' for transplantation of
human tumour tissue and for treatment experiments in nude mice.
Fresh STS tumour tissue was derived from adult patients.
Within 2 h after removal oftumour tissue, fragments with a diam-
eter of 2-3 mm were cut and implanted s.c. into both flanks of 8-
to 10-week-old nude mice. Upon growth. tumours were measured
weekly in three dimensions with a slide caliper. The volume was
calculated by the equation length x width x height x 0.5. and
expressed in mm". A tumour was considered to have a positive
take when the volume increased to > 50 mm3. When tumours
reached a size beyond 100 mm. serial transplantation (passage)
was carried out in further recipients. A xenograft was considered
to be established when more than three passages were obtained
and regrowth was successful from tumour tissue frozen in liquid
nitrogen. In addition, xenografts were established from a human
liposarcoma cell line WLS-160. kindly provided by Dr Y
Hirshaut. New York. NY. USA (Feit et al. 1984).
Human origin of STS xenografts
Tumour tissue of patients was examined by light microscopy.
immunohistochemistry and electron microscopy. The residual part
ofthe tissue used for transplantation as well as tumour samples of
further passages in the mouse were subjected to light microscopy.
Staining of paraffim-embedded sections included haematoxylin-
eosin. periodic acid Schiff(PAS). PAS-diastase and alcian blue. In
each passage. tumour samples were compared with the tumour of
origin for retention ofthe histological appearance.
Analysis ofthe lactate dehydrogenase (LDH) isoenzyme pattem
was carried out in all established xenografts. Briefly. 500 mg of
tumour tissue was minced mechanically in 2.5 ml 0.05 M sodium
barbital buffer (pH 8.6). After centrifugation. 7 tl of the super-
natant was prepared for electrophoresis by means of the Paragon
LDH Isoenzyme Electrophoresis Kit (Beckman. Fullerton. CA.
USA). Human serum and serum from non-tumour-bearing mice
were used as controls.
Drugs and treatnent
Doxorubicin (Farmitalia Carlo Erba. Nivelles. Belgium) dissolved in
water 2 mg ml-I and vincristine 1 mg ml-' (Eli Lilly. Nieuwegein.
The Netherlands) diluted in sodium chloride 0.9% to 0.2mg ml-'
were injected i.v. weekly for 2 weeks at the respective doses of
8 mg kg-' and I mgkg-'. Cyclophosphamide (ASTA-Medica.
Frankfurt. Germany) dissolved in water 50mg ml-'and ifosfamide
(ASTA) dissolved in water 20 mg ml-' were given i.p. twice with
2 weeks in between at the respective doses of 150mg kg' and
250 mg kg-' within 3 h of drug preparation. Etoposide 20mg ml-'
(Bristol-Myers Squibb. Woerden. The Netherlands) was further
diluted in sodium chloride 0.9% to I mg ml-' and was administred
at adose of7 mgkg-' i.p. daily x5. Drug doses were maximum toler-
ated in the schedules applied in our laboratory and published earlier
for doxorubicin. vincristine. cyclophosphamide and ifosfamide
(Boven et al. 1989. 1990). At the maximum tolerated dose. tumour-
bearing nude mice showed areversible weight loss of 10-15% ofthe
initial weight within 2 weeks afterthe initiation of ratment
Table 2 Growth inhibitior by singre agentsb in human soft tissue sarcoma xenografts
Xenogaft DOX CTX IFOS VCR VP16 Patient responsec
Gt# GI% GI% GI% GI%
S.Ba 35 (-) 86 (++) 46 (-) 36(-) 54(+) No chemotherapy
WLS-160 87 (++) 81 (++) 76 (++) 24(-) 42(-) Chenherapy unknown
S.Lt 61 (+) 51 (+) 30 (-) 60 (+) 24 (-) DOX: SD
S.To 39 (-) 35 (-) 55 (+) 24 (-) 11 (-) CYVADIC/DOX: Prog
S.Hh 49 (-) 32 (-) 19 (-) 38 (-) 19 (-) DOX + IFOS: SD
S.Hu 40 (-) 0 (-) 12 (-) 28 (-) 20 (-) CYVADIC: PR; IFOS: Prog
S.La(C) 32 (-) 29 (-) 29 (-) 61 (+) 13 (-) CYVADIC/DOX: Prog
S.Zu 56 (+) 60 (+) 59 (+) 86 (++) 12 (-) No chemotherapy
S.Ho 47 (-) 80 (++) 87 (++) 35 (-) 0 (-) CYVADIC: SD; DOX: Prog
S.Sin 93 (++) 69 (+) 54 (+) 76 (++) 29 (-) DOX: SD
MRI-H207d CR (++) CR (++) CR (++) 99.9 (++) 99.8 (++) CTX: CR
aGrowth inhition (GI%) >75% ++; >50%/6 to . 75% +;.50% -; CR, completeremission. bDOX, doxorubicin; CTX,cyckophaspharide; IFOS, ifosfamide; VCR,
vincristine; VP16, etoposide. cCYVADIC, combinaton ofcycophosphamide, vincristine, doxorubin and dacarbazine; CR, complete remission; PR, partial
response; SD, stable disease; Prog, progressiversease. M4RI-H-207 is a human ovarian cancer xenograft highly responsive to avarlety of drugs.
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Table 3 Human soft tssue sarcoma xenografts: expression of MDR1 and topoisomerase la. tissue levels of glutathione and actvrbes of glutathione-
dependent enzymes
Xenograft MDR1 Topo Ilaa GSIP GSTC GPXc GRc
S.Ba + 0.48 ± 0.27 9.4+ 3.8 34.4 ± 9.4 9.4 ± 3.4 43.2 ± 10.4
WLS-160 + 0.85±0.53 49.0±7.9 122.7±2.1 22.7±3.2 68.0±9.2
S.Lt - 0.14 ± 0.04 67.7 ± 9.7 304.3 ± 45.3 24.0 ± 4.0 80.0 ± 11.3
S.To - 0.29 ± 0.09 44.3+ 9.1 151.0 ± 5.0 24.3 ± 3.1 23.7 ± 1.5
S.Hh - 0.43 ±0.39 41.0 ± 5.6 185.7 ± 4.2 11.3 ± 2.3 27.3± 2.1
S.Hu - 1.00±0.00 40.0±6.5 62.6± 12.2 7.0 ± 1.2 99.6± 13.6
S.La(C) - 0.11 ±0.13 48.3± 16.6 49.2 ± 27.1 28.3 ± 6.4 34.0± 11.1
S.Zu - 0.04 ± 0.05 34.7 ± 14.5 71.0 ± 8.5 26.3 ± 4.2 51.0 ± 13.0
S.Ho + 0.44 ± 0.25 44.0 ± 6.8 134.6 ± 25.8 23.0 ± 2.1 22.4 ± 8.9
S.Sin - 0.46+ 0.08 27.7 ± 2.1 52.7 ± 0.6 25.0 ± 2.0 42.3 ± 3.1
MRI-H-207d - 1.46 ± 0.73 24.7 ± 2.9 90.3 ± 6.4 15.0 ± 1.0 47.0±2.0
aTopoisorase llaexpression relative to S.Hu ± s.d. bGlutathione (GSH) in nmol mg-' protein ± s.d. cGlutathione S-transferase (GST), glutathione peroxidase
(GPX) and glutathione reductase (GR) in nmol min-' mg-' protein + s.d. dDrug-sensifive human ovarian cancer xenograft
Table 4 Glutathione S-transferase isoenzye
Xenografl GST-a GST-l GST-t
S.Ba NAt NA NA
WLS-160 101 ±62 ND 1875 ± 370
S.Lt NDc 895 ± 301 3247 ±602
S.To 380± 120 847±164 2031 ± 139
S.Hh 2262+ 345 183 ±43 1583 ± 442
S.Hu ND ND 258 ± 22
S.La(C) ND ND 698 142
S-Zu ND ND 308±30
S.Ho ND ND 1424 540
S.Sin 102+8 ND 196±42
MR14-207 367 ± 158 ND 1137 385
aExpressed as ng mg-, protein (mean ± s.d.). bNotavailable, too low protein
content cNot detectable, limit of detecon is 40 ng mg-1 protein.
Chemotherapy experiments were started at the time s.c. tumours
had a mean volume of approximately 100 mm1 (designated as day
0). Treatment and control groups consisted of 5-7 mice each. The
increase in tumour volume from the start oftreatment(Vd) until the
value at any given time (V) was calculated for each tumour and
expressed as the relative tumour volume (Vt/Vd) on the day of
measurement. The mean of these values was used to calculate
the efficacy as a ratio between teated (T) and control (C)
tuhmo (T/C x 100%). Growth inhibition was expressed as
100% - (T/C x 100%). T'he highest percentage reached on a partic-
ular day within 5 weeks after the last drug administration was
considered the optimal growth inhibition. Tumours that had not
reached 20 mm at the start of treatment were considered inevalu-
able. Complete remissions representedtumours that were not visible
for a period ofat least 4 weeks. Animals dying within 2 weeks after
the final injection were considered toxic deaths and were excluded
from the evaluation. A drug was considered to be active when the
growth inhibition was > 50%7c. very active > 75% and inactive ifthe
growth inhibition was < 50% (Boven et al. 1988).
MDR1 and topoisomerase Ila expression
Tumour tissue was collected from various passages of established
STS xenografts for the expression of the MDRJ gene and the
topoisomerase IHa gene in three samples of different tumours of
each STS line. Tissues were stored in -70°C until use.
Frozen tumour tissues were pulverized in a microdismembrator
and total cellular RNA was isolated by acid-guanidinium-thio-
cyanate-phenol-chloroform extrction (Chomczynski and Sacchi.
1987). For the expression of the MDRJ gene. RNAase protection
was performed as described earlier (Broxterman et al. 1995). In
brief. RNA samples (10 jg) were hybridized with a [a32P]CTP-
labelled anti-sense RNA probe specific for human MDR] mRNA.
which was obtained by transcription of a 301-nucleotide MDR]
cDNA fragient (positions 3500-3801) with SP6 RNA polymerase.
For measurement oftopoisomerase Ha expression. 10 g of total
cellular RNA was used [a-'P]-labelled RNA complementary to the
topoisomerase HacDNA sequence (nucleotides 1277-2440) inserted
in the Xba-I site of pGEM4. was transcribed from Bgl H-linearized
DNA with the use ofSP6 RNA polymerase. RNAase protection was
carried out as describedpreviously (Klumperet al. 1995).
For both the MDRJ gene and topoisomerase IHa expression a
y-actin probe was included as a control for RNA recovery. The
hybridized probes were visualized after electrophoresis through a
denaturing 6% acrylamide gel. followed by autoradiography
(exposure to Kodak XS film overnight at -70°C). The amount of
MDRJ and topoisomerase IHa mRNA relative to the amount ofy-
actin was calculated by densitometric scanning ofautoradiograms.
Glutathione and glutathione-dependent enzymes
For determination of glutathione contents and of glutathione-
dependent enzymes. the tissues from three separate tumours per
STS xenograft. stored at -70°C. were thawed and subsequent
procedures were carried out on ice. Each sample was homogenized
for 60 s in 1 ml of 0.2 .M potassium phosphate buffer at pH 6.5
(Omni-1000 homogenizer. Omni International. Waterbury CT.
USA). Supernatants ofhomogenates were collected after centrifu-
gation at 100 000 g for 60 min and immediately used for enzyme
determination. The total protein content was determined with the
BCA protein assay reagent (Pierce Europe. Rockford. IL. USA).
Bovine serum albumin was used for standardization. Total
glutathione was measured by high-performance liquid chromatog-
raphy (HPLC) (Waters. Milford. MA. USA) as described previ-
ously (Neuschwander-Tetri and Roll. 1989). Peaks were detected
by fluorescence at 420 nm after excitation at 340 nm and
compared with a standard glutathione curve.












Figure 1 Haematoxyfirneosin-stained sections of soft-tissue sarcoma tissue from patients (A, B, C) and from the corresponding xenografts: (D) liposarcoma
S.Ba in passage 2: (E) malignant fibrous histiocytoma S.La(C) in passage 3: (F) neurofibrosarcoma S.Sin in passage 2. Bar = 0.35 um
Glutathione S-transferase activitv w-as measured w-ith 1-chloro-
2.4-dinitrobenzene (CDNB) as a substrate by adaptation of the
method of Habig et al (1974) to use a Cobas Bio centrifuyal
analyser (Roche Diagnostics. Basle. Switzerland). The increase in
extinction at a w-axelength of340 nm was a measure ofthe enzyme
actixitv. For rlutathione peroxidase actix itx. samples were
pretreated with glutathione and reduced nicotinamide adenine
dinucleotide phosphate (NADPH) to reduce oxidized glutathione
according to Laswrence and Burk ( 1976). Afterstarting, the reaction
Aith the addition of t-butyl hydroperoxide. the rate ofthe decrease
in extinction at 340 nm w-as determined. For measurement of
glutathione reductase. oxidized glutathione % as added to the
sample in the presence of NADPH. as described by Carlberg and
Mannervik (1985). The decrease in extinction at 340 nm was
measured to express the activity of glutathione reductase.
The isoenzvme composition of glutathione S-transferase w-as
determined according to the method of Peters et al (1992) based
on sodium dodecxl sulphate polvacrvlamide ael electrophoresis




FIgure 2 RNase protection assay on 10 ig RNA using MDR1 and --actin probes. MDR1 mRNA levels are shown in human soft-issue sarcoma xenografts.
Human epidermoid carcinoma cell lines KB3-1, KB8 and KB8-5 are used as references. The position ofthe protected fragments Ls indKicated. Probes for MDR1
and -f-actin are shown in the Lanes designated
(SDS-PAGE) and subsequent Westem blotting. Homogenates
from two different tumours per STS xenograft were analysed in
triphicate. The Westem blots were treated with monoclonal anti-
bodies against c. j. and x isoenzymes. The specific binding ofthe
monoclonal antibodies to their antigens was detected using 4-
chloro-l-naphthol after incubation with peroxidase-conjugated
rabbit anti-mouse secondary antibodies. The staining on the
immunoblots was quantified by densitometry and absolute
amounts were calculated with the use of purified isoenzymes run
in parallel as standards. The detection limi't of the method was
approximately 40 ng mg-- protein.
Statistics
Linear regression analvsis wx-as used to determine a possible rela-
tionship between the chemosensitivitv ofthe STS lines in vivo and
the vanrous drug resistance charactenstics.
RESULTS
Establishment of STS xenografts
A total of 23 tumour samples were obtained from 19 patients
known or presumed to have STS. In three patients. tissue was
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axailable on separate occasions. Upon diagnosis. one patient u-as
found to have extensix-e intra-abdominal carcinoid and another had
extraosseous osteogenic sarcoma. These patients u-ere excluded
from further analy-sis. A positive take >-as obtained in eight out of
ten samples of primary tumours and in 8 out of 11 samples of
metastases. A total of ten STS xenografts could be established.
fixve of primary tumours and fixve of metastases. A fibrosarcoma
xenograft was lost in further passages because tumour tissue
became inxaded by mouse lymphocytes (Boven. 1991a). The
xenografts that could not be transferred >3 passages invariablv
sho\ ed a tumour volume doubling time >30 davs.
Ten human STS xenografts w-ere analNsed for the retention of
specific features of the human tumour sample. Light microscopy
of xenoLraft tissue u-ith the use of conxventional stainin2 tech-
niques confirmed the resemblance of the histological pattern wxith
that of the orinsinal tumour tissue (Figure 1). The presence of
human LDH isoenzxmes in tumour tissue extracts persistentlI
indicated the human origin, except for the occurrence of a mouse
LDH isoenzyme pattern in the STS xenograft oxergrown by
mouse lymphocvtes (Boxven. 1991a). The present panel of STS
xenog,rafts. including- WLS-160 g,roown from a liposarcoma cell
line. consists of ten tumours and fixve histological subtypes. The
mean tumour volume doubling time xaries betwxeen 5.0 and 19.5
days (Table I
Chemosensitivity
The \veekly or exerx 2 weeks injection schedules for doxorubicin.
cyclophosphamide. ifosfamide and Xincristine in use in our labora-
torx (Boxen et al. 1989. 1990) wuere derixved from the clinic. u-here
drugs are generally administered on an intermittent base. For
etoposide. a daily schedule that u-as desisned as fractionated treat-
ment in patients was superior to sinale-dose injections (Slexvin
et al. 1989). A dose-findingz study of etoposide xas carried out in
non-tumour-bearing nude mice With doses of5 and 7.5 mg, kg-I i.p.
dailv x 5. xxhich resulted in a mean wxei2ht loss of 3.5%T and 15.2"
respectively. The selected dose of 7 mg kg- i.p. daily x S appeared
to be the maximum tolerated dose in tumour-bearing nude mice.
Upon analysis of the toxicitx data. it xxas found that each drug
caused <4A' toxic deaths.
Anti-tumour actixity expressed as growxth inhibition >75%c xxas
reached for doxorubicin in txxo xenografts. for cyclophosphamide
in three. for ifosfamide in txxo. for xvincristine in tx o and for etopo-
side in none of the STS xenografts (Table 2). The efficacy of
cyclophosphamide and ifosfamide xxas in the same range. except
for S.Ba. in xxhich cxclophosphamide xas more effectixe. The
experiments in S.Ba xere repeated and the growth inhibition for
cyclophosphamide x as 90% and that for ifosfamide xxas 27%C.
Chemosensitixvity betx een the xenografts xaried: S.Hh. S.Hu.
S.La(C) and S.To xxere most resistant. xhereas S.Sin and S.Zu
xxere most sensitixe.
Sexen patients from xhom tumours xxere excised xere treated
xith drugs for adxvanced or recurrent disease and the response xxas
scored accordin2 to WHO criteria (CXHO. 1979). Fixe of these
patients receixed combination as first-line chemotherapy and. there-
fore. comparisons xxith the chemosensitix ity of the STS xenografts
cannot be draxn. In general. treatment results xxere poor (Table 2'.
One patient obtained a partial response upon treatment xxith
CYV\ADIC. although the corresponding STS xenograft. S.Hu. xxas
not sensitixe to any- drug. Six patients received a single agent in the
course of their disease of xxhom four shoxxed progression and the
corresponding xenografts shoxed resistance. In S.Lt. doxorubicin
induced !rowth inhibition of 61 c. xxhereas the patient had stable
disease. Another patient had stable disease on doxorubicin. although
the xenograft S.Sin shoxxed high sensitixitv to that drug. The txxo
patients from x hom S.Ba and S.Zu xxere derix-ed had bulky progres-
sixe disease and x ere too old to receix-e chemotherapy.
MDR1 and topoisomerase llct expression
The MDR1 gene xxas detectable in the three STS xenografts S.Ba.
S.Ho and WLS-160 (Figure 2. Table 3'. The expression of the
MDRJ gene xas most pronounced in S.Ba. but this xas xxeaker
than the expression in an equal amount ofRNA ofthe MDRI-posi-
tixe cell line KB8-5 (Broxterman et al. 1995). Although S.Ba and
S.Ho wxere found to be resistant against doxorubicin and
xincristine. doxorubicin could clearly induce groxth inhibition in
ALS-160 tumours. Resistance to these agents xxas also obser-ed
in MDRI-negative STS xenografts.
SliTht variations wxere found in the extent of topoisomerase lIat
expression between tumours ofthe same STS xenograft. The three
tumours of S.Hu demonstrated a constant expression wxith respect
to a knowxn amount of topoisomerase Ila in the control human
lung cancer cell line NCI-N4 17 (Giaccone et al. 1992'). and
receix-ed the -alue of 1.00 (Table 3. In the three separate experi-
ments. all tumours xxere calculated as a relatixe xvalue of the
respectixe S.Hu tumours and inxariably shoxxed a lowxer expres-
sion. No relation could be found betxxeen the anti-tumour effects
ofdoxorubicin (r-xvalue of0.15 ) or etoposide (r-value of0.37 and
the amount of topoisomerase IIcl. In comparison. a human oxanran
cancer xenograft MRI-H-207. xhich is hiThlxv sensitixe to xarious
drugs. contained a higher topoisomerase Ila lexel than any STS
xeno-raft.
Glutathione and glutathione-dependent enzymes
Glutathione concentrations xaried betxeen 9.4 and 67.7 nmol mo-l
protein in the ten STS xenografts (Table 3). The xaniation in
2lutathione S-transferase enzyme actixvity xxas more pronounced
than the differences in glutathione peroxidase and reductase actixi-
ties among the xenografts. Glutathione and related enzymes xere
also measured in the drug-sensitixe human oxvarian cancer
xenoaraft MRJ-H-207. In companrson xith tumour tissue of the
STS xenografts. lox- to intermediate xalues could be detected.
Glutathione concentrations or the enzvrme actixvities in the STS
tumours did not shox a relationship xxith the efficacy of doxoru-
bicin (r-xvalues 0.15-0.29). cyclophosphamide (r-xvalues 0.04-0.33
or ifosfamide r-xvalues 0.09-0.49).
Isoenzyrme detection rexvealed a predominant expression of
glutathione S-transferase nt in the nine STS xenoarafts anal-sed
(Table 4). The oa and p isoenzymes xere only detectable in four
and three xenografts respectivelv. The amount of glutathione S-
transferase it correlated highly xxith the total enzyrme actixitx-
measured in the cvtosol (r-xvalue of 0.93).
DISCUSSION
For many years. wxe haxe obtained experience in the establishment
of. the characterization of and dru2 efficacv testin2 in human
tumour xenografts groxxn s.c. in the nude mouse (Wino2rad et al.
1987: Boxen et al. 1988. 1992: Boxen. 1991a: Molthoff et al.
1991: Langdon et al. 1994). In general. the tak-e rate depends on
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the tumour type of origin. in which STS shows a relatively good
transplantability and, for example. breast cancer remains a poorly
transplantable tumour type. For STS. initial take rates of 52-75%
have been reported. whereas 39-56% of the attempts have
succeeded in serial transfers (Winograd et al. 1987). Our results of
76% positive takes and 48% of transplantable STS xenografts
(including the STS xenograft lost in further passages) compare
favourably with the previous data. Transplantable xenografts
orossly retain the original features upon serial transfer. such as
histology. histochemistry. antigen expression. receptors for growth
factors. human lactate dehydrogenase and human chromosomes.
and keep a consistent growth rate (Boven. 199la). It is mandatory
to monitor specific properties. such as volume doubling time and
histology, as occasionally tumour tissue may be extensively
invaded by mouse stromal tissue or. in the case of one of our STS
xenografts. completely replaced by mouse lymphoproliferative
cells (Boven. 1991a).
Nine STS xenografts were established from patients that needed
chemotherapy in the course of their disease. These xenografts
indicated that doxorubicin. cyclophosphamide. ifosfamide and
vincristine had low activity in this tumour type, whereas etoposide
was inactive. In general. the results reflect clinical findings. in
which the response rates for single agents are for doxorubicin
13-34%. cyclophosphamide 0-16%. ifosfamide 7-38%.
vincristine 0-40% and etoposide 6-16% (Demetri and Elias.
1995). Budach et al (1994) have tested a single dose of doxoru-
bicin (10 mg kg-' i.v.) in 16 STS xenografts and the sensitivity
(calculated as specific growth delay >3) was only 13%. For a
single dose of ifosfamide (350 mg kg' i.p.). however, the sensi-
tivity was reported to be 63%. It is always difficult to compare
drug efficacy data with those obtained by other investigators. when
the methodology is not the same. In this respect. a number of
European institutes familiar with the nude mouse-human tumour
model have defined guidelines for 'preclinical' phase II studies
(Boven et al. 1988). Subsequent studies have revealed that
screening of new drugs in a disease-oriented approach becomes
feasible with the use of these guidelines (Boven et al. 1992:
Langdon et al. 1994). Our panel ofhuman STS xenografts appears
to be a valuable addition to the system of secondary drug testing.
Human tumour xenografts are an elegant tool to compare the effi-
cacy of new analogues with that of the parent compounds (Boven.
1991b). Tbere are. however. some disadvantages related to differ-
ences between species. because the phamacology and the side-
effects ofthe analogue mayfollow adifferentpattem than those ofthe
parent compound- Pefraps ifosfamide is such a compound because.
unlike in STS patients. we could not confirm its superiority to
cyclophosphamide. This may be explained by differences in drug
doses tolerated which was for ifosfamide 1.7-fold higher than for
cyclophosphamide in the mouse. whereas ifosfamide in patients can
be dosed five times higher than cyclophosphamide upon mesna
uroprotection. TreatmentofSTSxenografts with higherdoses ofifos-
famide may result in a higher response rate as indicated by the 63%
sensitivity in 16 xenografts trated with a single dose of 350mg kg-'
i.p.byBudach etal ( 1994).
Adult STS can be considered as a moderately chemoresponsive
tumour type in the clinic. The majority of patients with advanced
disease will not respond or will show progressive disease regard-
less of the type of chemotherapy. Intrinsic resistance against
doxorubicin. vincristine oretoposide does not seem to be related to
MDR] gene expression as analysed in our STS xenografts. For
adult STS in the clinic. a clear correlation between MDR] and a
poor response to chemotherapy has also not been demonstrated
(Stein etal. 1996).
Most studies on reduced topoisomerase II mRNA levels.
reduced enzyme activity or mutated topoisomerase II have been
carried out in human malignant cell lines selected for resistance
against epipodophyllotoxins or anthracyclines (Nitiis and Beck.
1996). Fry et al (1991) have shown that unselected cell lines from
testicular cancer had a higher capacity to induce topoisomerase II-
mediated DNA strand breaks than bladder cancer cell lines. In cell
lines from small-cell lung cancer. it has been found that topoiso-
merase II catalytic activity and topoisomerase II nuclear protein
content were higher than in non-small-cell lung cancer cell lines
(Kasahara et al. 1992). In eight unselected human lung cancer cell
lines. Giaccone et al (1992) have found a high correlation between
topoisomerase II gene levels and sensitivity to epipodophyllo-
toxins and doxorubicin. In contrast. topoisomerase Ha mRNA
expression did not correlate with the in vitro chemosensitivity of
acute lymphoblastic leukaemia in children (Klumper et al. 1995).
We did not find a relationship between topoisomerase Ha mRNA
levels and chemosensivity in STS xenografts. In contrast. the
mRNA levels measured were consistently lower than the level in
the human ovarian cancer xenograft MRI-H-207. which is highly
sensitive to doxorubicin and etoposide.
Cellular glutathione levels are a determinant for sensitivity to
alkylating agents and significant glutathione S-transferase activity
has been found in tumour cells intrinsically resistant to such drugs
(Black and Wolf. 1991; Tew. 1994: Hayes and Pulford. 1995). It
has been suggested that elevated glutathione S-transferase x iso-
enzyme levels are a marker for drug resistance (Black and Wolf.
1991). The roles of glutathione peroxidase and reductase in drug
resistance are less clear (Black and Wolf. 1991). Most information
on glutathione and glutathione-dependent enzymes in unselected
cell lines has been obtained by measuring the sensitivity to
cisplatin. In eight human small-cell lung cancer cell lines. Sharma
et al (1993) have described that of the four parameters measured
only glutathione S-transferase activity correlated with the degree
of cisplatin resistance. Hida et al (1993) have reported higher
glutathione S-transferase xc levels in human lung cancer cell lines
with low sensitivity to cisplatin. In cell lines from head and neck
cancer. Yellin et al (1994) have found an inverse relationship
between cisplatin sensitivity and glutathione contents. but not
glutathione S-transferase it mRNA expression. We compared
glutathione concentrations and glutathione-dependent enzyme
activities with the in vivo sensitivity to cyclophosphamide and
ifosfamide. but no correlations could be found. However. levels of
glutathione and glutathione S-transferase activity in the human
ovarian cancer xenograft were low to intennediate when compared
with values in STS lines. whereas in MRI-H-207 tumours the
alkylating agents could induce complete remissions.
Our panel of human STS xenografts grown as s.c. tumours
reflects the clinic in terms of retention of the histoloy,. human
LDH isoenzymes and chemosensitivity pattem. The drug resis-
tance characteristics examined in these xenografts do not explain
the reasons for the moderate responsiveness of STS to the various
anti-cancer agents tested. Topoisomerase Ila mRNA levels were
relatively low. which may partly account for intrinsic resistance
against e.g. doxorubicin. DNA repair mechanisms may possibly
contribute to the moderate responsiveness to alkylating agents.
Doxorubicin resistance has been observed in tumour cells that
express the major vault protein encoded by LRP (Slovak et al.
1995) or the multidrug resistance-associated protein MRP (Cole et
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al. 1994). Our STS xenografts will probably be of value in
elucidating other disease-related resistance mechanisms. towards
which compounds may be generated that improve the treatment
outcome in this malignancy.
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